RetractedTrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

Stephen R D Johnston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.